"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
HYPERSENSITIVITY TO ANY COMPONENT OF THE VACCINE, INCLUDING THIMEROSAL AND DIPHTHERIA TOXOID, IS A CONTRAINDICATION TO USE OF THIS VACCINE.
Last reviewed on RxList: 3/9/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Prohibit Information
Report Problems to the Food and Drug Administration
Find out what women really need.